The world of biotechnology is in the midst of a wave of exciting research and clinical advances, from artificial intelligence-driven drug discovery to cell and gene therapy, precision genome editing and other emerging technologies. These advances are driving new treatments for patients and fueling a resurgence in markets that are generating capital for the industry, from venture capital supporting private start-ups to initial public offerings for more mature companies.
GEN’s flagship virtual event, “The State of Biotech” (sponsored exclusively by Cytiva), proudly hosts a group of outstanding research and business leaders from industry and academia to discuss the latest R&D, innovations, disruptive technologies and regulatory changes that are driving biotech forward to bigger and better for patients around the world.
Join us on September 11th for the following exciting programs:
Opening keynote by David Altshuler, MD, PhD, Executive VP and Chief Scientific Officer, Vertex Pharmaceuticals Keynote by John Crowley, President and CEO, Biotech Innovation Organization (BIO) By popular demand, co-hosts of the popular Biotech Hangout podcast Daphne Zohar, Brad Loncar, and Chris Garabedian reflect on the rise and fall of the biotech sector A timely discussion on the current state of artificial intelligence in biotech with industry experts from Google, NVIDIA, and Recursion A conversation with Tim Harris, author of the new book, In Pursuit of Unicorns: A Journey through 50 Years of Biotechnology, an inspiring memoir chronicling the history of biotech Forging the Path to CRISPR Therapeutics with Dr. Brad Ringeisen (IGI) and Dr. Sadik Kassim (Danaher) Parallel breakout sessions hosted by Cytiva
State of Biotech is GEN’s flagship virtual event, following a successful launch and expansion last year in 2022. Registration is completely free.
